Ankyra Medical Journal (AnkMJ), formerly known as the Journal of Translational and Practical Medicine, regularly publishes international quality issues in the field of Medicine in the light of current information.

EndNote Style
Anemia in chronic kidney disease
Anemia associated with chronic kidney disease is a common complication and a cause of increased morbidity and mortality. Hemoglobin levels should be closely monitored in all stages of chronic kidney disease. In this review, current clinical practice for anemia associated with chronic kidney disease, including pathophysiology, diagnosis, and treatment management, is reviewed.

1. Levin AS, Bilous RW, Coresh J. Chapter 1: definition and classificationof CKD. Kidney Int Suppl. 2013;3(1):19-62.
2. Levin A, Stevens PE, Bilous RW, et al. Kidney disease: improving globaloutcomes (KDIGO) CKD work group. KDIGO 2012 clinical practiceguideline for the evaluation and management of chronic kidneydisease. Kidney Int Suppl. 2013;3(1):1-150. doi: 10.1038/kisup.2012.73
3. Lefebvre P, Vekeman F, Sarokhan B, Enny C, Provenzano R, CremieuxPY. Relationship between hemoglobin level and quality of life in anemicpatients with chronic kidney disease receiving epoetin alfa. Curr MedRes Opin. 2006;22(10):1929-1937. doi: 10.1185/030079906X132541
4. Astor BC, Coresh J, Heiss G, Pettitt D, Sarnak MJ. Kidney functionand anemia as risk factors for coronary heart disease and mortality:the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J.2006;151(2):492-500. doi: 10.1016/j.ahj.2005.03.055
5. Kovesdy CP, Trivedi BK, Kalantar-Zadeh K, Anderson JE. Associationof anemia with outcomes in men with moderate and severe chronickidney disease. Kidney Int. 2006;69(3):560-564. doi: 10.1038/
6. Nissenson AR, Wade S, Goodnough T, Knight K, Dubois RW. Economicburden of anemia in an insured population. J Managed Care Pharmacy.2005;11(7):565-574. doi: 10.18553/ jmcp.2005.11.7.565
7. Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022.Kidney Int Suppl. 2022;12(1):7-11. doi: 10.1016/j.kisu.2021.11.003
8. Shaikh H, Hashmi MF, Aeddula NR. Anemia of Chronic Renal Disease.2023 Feb 24. In: StatPearls [Internet]. Treasure Island (FL): StatPearlsPublishing; 2024 Jan-. PMID: 30969693.
9. Bishaw F, Belay Woldemariam M, Mekonen G, Birhanu B, Abebe A.Prevalence of anemia and its predictors among patients with chronickidney disease admitted to a teaching hospital in Ethiopia: a hospital-based cross-sectional study. Medicine. 2023;102(6):e31797. doi: 10.1097/MD. 0000000000031797
10. Portolés J, Gorriz JL, Rubio E, et al. The development of anemia isassociated to poor prognosis in NKF/KDOQI stage 3 chronic kidneydisease. BMC Nephrol. 2013;14(1):2.
11. Süleymanlar G, Utaş C, Arınsoy T, et al. A population-based surveyof Chronic Renal Disease in Turkey-the CREDIT study. Nephrol DialTransplant. 2010:26(6);1862-1871.
12. Ateş K, Seyahi N, Koçyiğit İ. Türkiye’de, Nefroloji-Diyaliz veTransplantasyon. Registry 2023. Türk Nefroloji Derneği Yayınları:2023.
13. Portolés J, Martín L, Broseta JJ, Cases A. Anemia in chronic kidneydisease: from pathophysiology and current treatments, to future agents.Front Med. 2021;8:642296. doi: 10.3389/fmed. 2021.642296
14. Schoener B, Borger J. Erythropoietin Stimulating Agents. [Updated2023 Mar 11]. In: StatPearls [Internet]. Treasure Island (FL): StatPearlsPublishing; 2024 Jan-. Available from:
15. Suresh S, Rajvanshi PK, Noguchi CT. The many facets of erythropoietinphysiologic and metabolic response. Front Physiol. 2020;10:1534.
16. Uysal Z. Hepsidin ve demir metabolizması. In: 6. Hematoloji İlkBasamak Kursu Eğitim Kitabı, Ulusal Hematoloji Kongresi. Ankara:2007:9-15.
17. Wu SG, Jeng FR, Wei SY, et. al. Red blood cell osmotic fragility inchronically hemodialyzed patients. Nephron. 1998;78(1):28-32.
18. Bonomini M, Sirolli V, Settefrati N, Dottori S, Di Liberato L, ArduiniA. Increased erythrocyte phosphatidylserine exposure in chronic renalfailure. J Am Soc Nephrol. 1999;10(9):1982-1990.
19. Linde T, Sandhagen B, Wikström B, Danielson BG. The required dose oferythropoietin during renal anaemia treatment is related to the degreeof impairment in erythrocyte deformability. Nephrol Dial, Transplant.1997;12(11):2375-2379.
20. Lin Y, Li C, Waters D, Kwok CS. Gastrointestinal bleeding in chronickidney disease patients: a systematic review and meta-analysis. RenFail. 2023;45(2):2276908.
21. Noxon V, Knopf KB, Norris LB, et al. Tale of two erythropoiesis-stimulating agents: utilization, dosing, litigation, and costs ofdarbepoetin and epoetin among South Carolina Medicaid-coveredpatients with cancer and chemotherapy-induced anemia. J Oncol Pract.2017;13(6):e562-e573.
22. Macdougall IC, Coles GA, Williams JD, et al. Long-termcardiorespiratory effects of amelioration of renal anaemia byerythropoietin. Lancet. 1990;335(8688):489-493.
23. Maddux FW, Shetty S, Aguila MAD, Nelson MA, Murray BM.Pharmacoeconomics: effect of erythropoiesis-stimulating agents onhealthcare utilization, costs, and outcomes in chronic kidney disease.Ann Pharmacother. 2007;41(11):1761-1769.
24. Perkins R, Olson S, Hansen J, Lee J, Stiles K, Lebrun C. Impact of ananemia clinic on emergency room visits and hospitalizations in patientswith anemia of CKD pre-dialysis. Nephrol Nurs J. 2007;34(2):167-173.
25. Schoener B, Borger J. Erythropoietin Stimulating Agents. 2023 Mar 11.In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing;2024 Jan-. PMID: 30725682.
26. Jelkmann W. Physiology and pharmacology of erythropoietin. TransfusMed Hemother. 2013;40(5):302-309.
27. McCullough PA, Barnhart HX, Inrig JK, et al. Cardiovascular toxicityof epoetin-alfa in patients with chronic kidney disease. Am J Nephrol.2013;37(6):549-558.
28. Winearls C, Pippard M, Downing M, Oliver D, Reid C, Cotes PM.Effect of human erythropoietin derived from recombinant DNA onthe anaemia of patients maintained by chronic haemodialysis. Lancet.1986;328(8517):1175-1178.
29. Chang W, Lo Y, Gao Z, Wu S. Evidence for the capability of roxadustat(FG-4592), an oral HIF prolyl-hydroxylase inhibitor, to perturbmembrane ionic currents: an unidentified yet important action. Int JMol Sci. 2019;20(23):6027. doi: 10.3390/ijms20236027
30. Czock D, Keller F. Clinical pharmacokinetics and pharmacodynamicsof roxadustat. Clin Pharmacokinet. 2022;61(3);347-362. doi: 10.1007/s40262-021-01095-x
31. Akizawa T, Yamaguchi Y, Otsuka T, Reusch M. A phase 3, multicenter,randomized, two-arm: open-label study of intermittent oral dosingof roxadustat for the treatment of anemia in Japanese erythropoiesis-stimulating agent-naïve chronic kidney disease patients not on dialysis.Nephron. 2020;144(8):372-382. doi: 10.1159/000508100
32. Cygulska K, Wejner-Mik P, Plewka M, Figiel L, Chrzanowski L,Kasprzak J. Roxadustat: another drug that causes pulmonaryhypertension? Report of first human case. Pol Arch Intern Med.2019;129(5):344-345. doi: 10.20452/pamw.4445
33. Liu J, Zhang A, Hayden J, et al. Roxadustat (FG-4592) treatment foranemia in dialysis-dependent (DD) and not dialysis-dependent (NDD)chronic kidney disease patients: a systematic review and meta-analysis.Pharmacol Res. 2020;155:104747. doi: 10.1016/j.phrs.2020.104747
34. Ogawa C, Tsuchiya K, Tomosugi N, Maeda K. A hypoxia-induciblefactor stabilizer improves hematopoiesis and iron metabolism earlyafter administration to treat anemia in hemodialysis patients. Int J MolSci. 2020;21(19):7153. doi: 10.3390/ijms21197153
35. Del Vecchio L, Locatelli F. Roxadustat in the treatment of anaemia inchronic kidney disease. Expert Opin Investig Drugs. 2018;27(1):125-133.doi: 10.1080/13543784.2018.1417386
36. Fudin R, Jaichenko J, Shostak A, Bennett M, Gotloib L. Correction ofuremic iron deficiency anemia in hemodialyzed patients: a prospectivestudy. Nephron. 1998;79(3):299-305.
37. Sarnak MJ, Levey AS. Epidemiology, diagnosis, and managementof cardiac disease in chronic renal disease. J Thromb Thrombolysis.2000;10(2):169-180.
38. Pisoni RL, Bragg-Gresham JL, Young EW, et al. Anemia managementand outcomes from 12 countries in the Dialysis Outcomes and PracticePatterns Study (DOPPS). Am J Kidney Dis. 2004;44(1):94-111.
Volume 3, Issue 1, 2024
Page : 24-27